Compare SEDG & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEDG | NNNN |
|---|---|---|
| Founded | 2006 | 2021 |
| Country | Israel | Germany |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2015 | 2025 |
| Metric | SEDG | NNNN |
|---|---|---|
| Price | $35.06 | $21.09 |
| Analyst Decision | Hold | |
| Analyst Count | 20 | 0 |
| Target Price | ★ $26.86 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 37.3K |
| Earning Date | 02-18-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | ★ $1,045,303,000.00 | $6,920,153.00 |
| Revenue This Year | $33.56 | N/A |
| Revenue Next Year | $15.45 | N/A |
| P/E Ratio | ★ N/A | $386.55 |
| Revenue Growth | ★ 2.35 | N/A |
| 52 Week Low | $11.00 | $5.18 |
| 52 Week High | $48.60 | $55.65 |
| Indicator | SEDG | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 60.17 | 35.63 |
| Support Level | $33.68 | $28.61 |
| Resistance Level | $36.00 | $31.52 |
| Average True Range (ATR) | 2.08 | 4.86 |
| MACD | 0.31 | -1.64 |
| Stochastic Oscillator | 76.72 | 10.10 |
SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.